Preclinical studies of HAE gene-editing therapy promising
An investigational gene-editing therapy for hereditary angioedema (HAE) called P-KLKB1-101 showed it could safely work as intended in preclinical studies, according to recent data. The treatment, developed by Poseida Therapeutics, successfully edited the KLKB1 gene and lowered levels of the kallikrein enzyme across experiments in lab-grown human liver…